Thermo Fisher Scientific (NYSE:TMO) Issues FY 2026 Earnings Guidance

Thermo Fisher Scientific (NYSE:TMO) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 24.930-25.330 for the period, compared to the consensus EPS estimate of 24.850. The company issued revenue guidance of $47.4 billion-$48.1 billion, compared to the consensus revenue estimate of $47.8 billion.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $567.34 on Friday. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.15. The company has a market capitalization of $210.83 billion, a price-to-earnings ratio of 30.52, a price-to-earnings-growth ratio of 2.51 and a beta of 0.87. The firm’s fifty day moving average price is $494.01 and its 200 day moving average price is $513.46.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the company posted $4.28 EPS. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts forecast that Thermo Fisher Scientific will post 25.08 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TMO shares. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $613.05.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher beat Q2 expectations on both earnings and revenue, reporting $6.03 in adjusted EPS versus $5.71 expected and $11.99 billion in revenue versus $11.71 billion expected, with organic revenue up 5% year over year. Reuters article
• Positive Sentiment: The company raised its FY 2026 guidance, signaling management’s confidence that customer demand recovery should continue and that the stronger quarter was not a one-off. Business Wire article
• Positive Sentiment: Analysts pointed to broad-based improvement in life sciences and biopharma activity, plus price target upgrades, as additional support for the stock’s rally. Yahoo Finance article
• Neutral Sentiment: Thermo Fisher also launched InstaFlux for food microbiology labs, a product announcement that may help long-term workflow adoption but is not likely the main driver of the stock move today. Business Wire article
• Neutral Sentiment: One analyst note suggested the strong quarter may not materially change the second-half outlook, indicating some caution after the earnings beat. Yahoo Finance article

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its stake in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC grew its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $170,000. Raymond James Financial Inc. grew its stake in shares of Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after purchasing an additional 53,542 shares in the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after purchasing an additional 2,262 shares during the period. 89.23% of the stock is currently owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.